Karen Beltz

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement.

Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement.

Journal: Journal of medicinal chemistry

Published: October 15, 2025

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.

Journal: Journal of medicinal chemistry

Published: November 22, 2024

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2024

Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.

Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.

Journal: Journal of medicinal chemistry

Published: January 04, 2024

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.

Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.

Journal: Journal of medicinal chemistry

Published: January 19, 2023

Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.

Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.

Journal: Journal of medicinal chemistry

Published: October 14, 2021

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.

Journal: Journal of medicinal chemistry

Published: November 20, 2020

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.

Journal: Frontiers in immunology

Published: January 17, 2020

Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.

Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2019

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Journal: EMBO molecular medicine

Published: September 19, 2018

Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.

Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.

Journal: Scientific reports

Published: October 07, 2015

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

Journal: Molecular neurodegeneration

Published: June 11, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026